Responses
Scientific Abstracts
Oral Presentations
AxSpA drug treatment: new and old drugs
OP0019 BIMEKIZUMAB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 24-WEEK EFFICACY & SAFETY FROM BE MOBILE 2, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED STUDY
Compose a Response to This Article
Other responses
No responses have been published for this article.